-+ 0.00%
-+ 0.00%
-+ 0.00%

HSBC Maintains Reduce on Biogen, Raises Price Target to $175

Benzinga·09/10/2026 14:09:39
Listen to the news
HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.